zurich the world health organization who said on tuesday that a safety team would review data on hydroxychloroquine by next month a day after officials cited safety concerns that prompted them to suspend use of the malaria drug in a global trial in covid19 patientsthe who called time on using the drug in its multicountry trial called solidarity after a study published in british medical journal the lancet found patients randomised to get hydroxychloroquine hcq had increased mortality rates and higher frequency of irregular heartbeats us president donald trump and others have pushed hcq as a possible treatment for the diseasea final decision on the harm benefit or lack of benefit of hydroxychloroquine will be made once the evidence has been reviewed by the data safety monitoring board the who said this review will include data from the solidarity trial and other ongoing trials as well as any evidence published so far it is expected by midjune